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ABSTRACT
 
This paper discusses the relations between different types
of patient-reported outcomes that may be collected in
clinical studies. Two models are presented that argue that
there is a linear relation between the different outcomes.
When needs-based quality of life (QoL) is incorporated
into the model it is proposed that a two-dimensional rela-
tion is more appropriate. The new model is illustrated by
data collected using different types of outcome measures.
Finally, the different outcomes are related to their purpose
in clinical studies.
Keywords: disability, impairment, patient-reported out-
come, quality of life, questionnaire.
 
Relations between Patient-Reported 
Outcomes
 
The constructs that fall within the remit of “patient-
reported outcome” have been deﬁned previously
[1]. The purpose of this paper is to show how these
constructs relate to each other and their value to
clinical trials. In the 
 
International Classiﬁcation of
Impairments, Disabilities and Handicaps
 
 (ICIDH)
[2] disease (or disorder), impairment, disability, and
handicap are seen as forming a linear progression.
However, not all impairments and disabilities result
in handicap. Similarly, impairment might lead
directly to handicap without any obvious disability
occurring (as with scarring of the face (impair-
ment)) which causes social-integration handicap. It
is also possible for a handicap to exist after the
causative impairment or disability has been
resolved, as with social-integration handicap result-
ing from psychological response to dermatological
conditions experienced during early life.
This conception of the relation between out-
comes partially supports an earlier one proposed by
Wilson and Cleary [3]. These authors attempt to
provide a theoretical link between clinical variables
and health-related quality of life (HRQL) outcomes.
In so doing they propose a wider linear progression
than that suggested by the World Health Organiza-
tion (WHO). Biological and physiological factors
are seen as the direct cause of symptoms (impair-
ment). Symptoms inﬂuence functioning (disability).
This directly inﬂuences “general health percep-
tions” which are described as an integration of the
outcome constructs preceding them in the progres-
sion and which are rated subjectively. In this respect
they approximate to the WHO’s handicap outcome.
The authors then argue that this outcome leads to
overall QoL, which they do not attempt to deﬁne,
referring to other researchers’ conceptions. Wilson
and Cleary also identify the impact that personal,
environmental, and other inﬂuences will have on
the relation between the different types of outcome
and the inﬂuence of nonmedical factors on QoL.
Brenner and colleagues [4] postulated ﬁve prin-
ciples that can be used to explain a causal link
between the outcomes of disease. They argue that
signs and symptoms (impairment) can be consid-
ered the most deﬁnitive and objective indication of
the presence of disease. Disease-speciﬁc functioning,
general functioning, and “general well-being”
(undeﬁned but also referred to by the authors as
quality of life (QoL)) are removed increasingly fur-
ther from the most direct indication of disease. In
the original publication the ﬁve principles were
expressed in terms of the impact of treatment. How-
ever, with the exception of Principle 3, they can be
adapted to allow an examination of the cross-
sectional relations between different types of out-
come, as shown in Table 1.
These  principles  can  be  illustrated  by  means
of the Longitudinal Investigation of Depression
Outcomes (LIDO) study [5], a cross-national ob-
servational study of major depression and its cor-
relates. LIDO employed a number of measures
designed to assess the potential outcomes of major
depression:
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• CES-D; The Center for Epidemiologic Studies
Depression Scale is a 20-item measure assessing
the frequency and severity with which symp-
toms of depression are experienced in the gen-
eral population [6].
• MHI-5: The Mental Health Index consists of
ﬁve items also included in the Medical Out-
comes Short Form-36 (SF-36), which assess
psychological well-being [7].
• SF-12: This scale is a forerunner of the SF-36
and consists of 12 items in the current scale said
to be a brief overall measure of health status [8].
• WHOQOL Bref: The 26-item version of the
World Health Organization Quality of Life
Assessment consists of four subscales; Psycho-
logical, Physical, Social, and Environmental [9].
• QLDS: The Quality of Life in Depression Scale
consists of 34 items. It is a needs-based QoL
instrument speciﬁc to major depression [10,11].
Table 2 shows the number and proportion of items
in each outcome measure assessing each type of
PRO as deﬁned in [1]. It is acknowledged that the
authors of some of these outcome measures might
not agree with some of the classiﬁcations.
The most direct measure of depression severity
available in the LIDO study was the CES-D. As
would be expected, its content is primarily impair-
ment. The SF-12 consists of 12 items, 4 assessing
impairment and 8 covering disability. All items are
used to calculate two subscale scores: Physical
Component Score (PCS) and Mental Component
Score (MCS). Different weights are applied to each
item in the two subscales, the highest weighted
items for the MCS primarily assess impairment and
for the PCS, the bias is towards disability.
The WHOQOL Bref psychological scale (WQ
Psych) consists of 6 items. Four of these clearly
assess impairment and two are concerned with
issues more closely related to needs-based QoL
(enjoyment and meaningfulness of life). For this rea-
son, the measure is considered to contribute to both
the impairment and QoL categories. Overall, the
content of the WHOQOL Bref represents a good
cross-section of the ICIDH categories, as would be
expected from the deﬁnition of “QoL” on which it
is based [12]. Of the 24 items that form the four
subscales, 29% assess impairment, 29% disability,
and 33% handicap.
Although all the items in the QLDS can be
related to needs, objectively some are also directly
related to impairment and disability. For example,
the item “I ﬁnd it hard to hold a conversation” can
also be seen as an indicator of disability. However,
all humans have the need to communicate with each
other.
Figure 1 places the outcome measures on a two-
dimensional measurement framework, which
reﬂects their content. A two-dimensional represen-
tation is selected in order to indicate that this is not
 
Table 1
 
Relation between different types of  outcome (after Brenner et al.) [2]
 
Principle 1: The greater the distance between disease and outcome measure, the weaker the association between them will be. The strength 
of  the association between outcome measures will also be related to their speciﬁcity to the disease being assessed. Disease-
speciﬁc outcomes will be closer to disease than more generic outcomes. Therefore, for example, associations between the 
CES-D and Quality of  Life in Depression Scale (two depression-speciﬁc outcomes) would be expected to be stronger than would 
be predicted by the absolute distance between them on the outcome framework.
Principle 2: The more severe the disease, the greater the impact will be on all outcome measures.
Principle 3: Related to principle 2. If  the pretreatment distal indicators (such as QoL) are at a relatively high level, there will be little room for 
treatment to inﬂuence them.
Principle 4: Distal outcomes will be inﬂuenced more markedly by external (nondisease) factors.
Principle 5: There is a causal chain linking each outcome measure to the next more distal outcome measure. Intermediate outcomes (between 
more proximal and more distal outcomes) can be considered to be “intervening variables”.
 
Table 2
 
Outcome constructs assessed by the instruments included in the LIDO study
 
Measure No. items
Impairment
 
n
 
 (%)
Disability
 
n
 
 (%)
Handicap
 
n
 
 (%)
QoL
 
n
 
 (%)
CES-D 20 19 (95) 1 (5)
MHI-5 5 5 (100)
SF-12 12 4 (33) 8 (67)
WHOQOL
Psychological 6 4 (67) 2 (33)
Physical 7 3 (43) 4 (57)
Social 3 3 (100)
Environmental 8 8 (100)
QLDS 34 6 (18) 2 (6) 26 (76)
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a simple linear relation between different types of
outcome construct. The vertical scale for the ﬁgure
is arbitrary. The QLDS is separate from the ICIDH
continuum as it primarily measures QoL. The WQ
Psych scale falls between the QLDS and the ICIDH
continuum as its content consists primarily of
impairment items. Although the actual distances
between outcomes in the ﬁgure are hypothetical, the
framework allows the relations between different
outcome constructs to be explored more accurately.
 
What Outcomes Should Be Measured in 
Clinical Trials?
 
Selection of the appropriate PRO is dependent on a
trial’s purpose [13]. Table 3 shows potential meas-
urement needs and the associated outcome
constructs.
In most clinical trials, disease severity and/or
treatment toxicity will be the primary outcome var-
iables. Here, measures that inform on the level of
impairment experienced by patients would be
selected. HRQL measures may also perform this
function, but too often they replicate the content of
clinical outcome measures without securing the
depth of measurement achieved by the latter. Where
it is considered likely that ability to perform activ-
ities will be affected, the assessment of disability
will also be of value. The assessment of handicap is
required where the perspective of society is consid-
ered relevant to the trial.
It  is  becoming  increasingly  common  for  trials
to include outcomes other than disease severity or
treatment toxicity as secondary endpoints. Here,
true QoL instruments become of utmost impor-
tance. It is likely that a reduction in severity of
symptoms in the absence of adverse treatment
effects will be perceived as beneﬁcial by the patient.
Nevertheless, none of the above outcomes are nec-
essarily the patient’s prime concern. Indeed, it may
be difﬁcult to determine whether improvements in
symptomatology outweigh treatment toxicity.
 
Implications for Interpreting the 
Meaningfulness of Quality of Life
 
A number of researchers judge the quality of out-
come measures in terms of their level of correlation
with measures of clinical severity or the extent to
which such measures change in parallel (see for
example [14,15]). Such judgments are ﬂawed when
comparisons are made between measures assessing
outcomes at different points in the outcome frame-
work shown in Figure 1. Furthermore, estimates of
the “clinical meaningfulness” of outcome measures
can be misleading when they rely on anchoring to
clinical outcomes. The concept of clinical meaning-
fulness in the context of true QoL assessment is
problematic. True meaningfulness should be estab-
lished with true experts—the patients—and this is
the process adopted when assessing construct valid-
ity. However, researchers still need to be able to help
clinicians interpret what absolute and change scores
on QoL measures imply.
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constructs
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Diagnosis Impairment
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Treatment toxicity Impairment
Patient functioning Disability (activity)
Rehabilitation planning Disability (activity)
Social service planning Handicap (disadvantage)
Overall impact of  disease and
its treatment
Quality of  life
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